| Company Name: | Merck & Co Inc | | Ticker Symbol: | MRK | | CIK Number: | 0000310158 | | WWW Address: | https://www.merck.com |
| CEO: | Mr. Kenneth C. Frazier | | No. of Employees: | 68,000 |
| Common Issue Type: | CS | | Business Description: | Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | Hoch | Low | Volume | | 82.78 |  -0.12 | - | - | 82.8 | 82.44 | 81.43 | 7645549 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 213,129.1 | 2,574.6 | 0.00 | 2.34 | 2.20 | 34.6 | 2.5 | 84.35 - 59.80 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 81.45 | $ | | PE Ratio - LTM | 34.6 | |
| Market Capitalisation | 213,129.1 | mil |
| Latest Shares Outstanding | 2,574.6 | mil |
| Earnings pS (EPS) | 2.34 | $ |
| Dividend pS (DPS) | 2.20 | ¢ |
| Dividend Yield | 2.5 | % |
| Dividend Payout Ratio | 1 | % |
| Revenue per Employee | 612,957 | $ |
| Effective Tax Rate | 0.3 | % |
| Float | 2,580.2 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.20 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.20 | % |
| Gross Profit Margin | 68.1 | % |
| EBITDA Margin | 33.1 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 49.6 | % |
| Return on Assets (ROA) | 7.3 | % |
| Return on Equity (ROE) | 20.4 | % |
| Return on Capital Invested (ROCI) | 11.8 | % |
| Current Ratio | 1.2 | |
| Leverage Ratio (Assets/Equity) | 3.1 | |
| Interest Cover | 12.3 | |
| Total Debt/Equity (Gearing Ratio) | 0.94 | |
| LT Debt/Total Capital | 43.0 | % |
| Working Capital pS | 1.43 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 10.70 | $ |
| Tangible Book-Value pS | -1.16 | $ |
| Cash Flow pS | 4.19 | $ |
| Free Cash Flow pS | 3.15 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.59 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 19.4 | |
| Price/Free Cash Flow | 25.8 | |
| P/E as % of Industry Group | 92.0 | % |
| P/E as % of Sector Segment | 132.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 2.20 |
| Current Dividend Yield | 2.5 |
| 5-Y Average Dividend Yield | 4.4 |
| Payout Ratio | 1.0 |
| 5-Y Average Payout Ratio | 155.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | Hoch | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.6 | | 9,056,935 | 37,757,940 |
| 4 Weeks | 82.44 | 76.28 | 78.19 | 4.2 | | 8,979,492 | 170,610,358 |
| 13 Weeks | 84.35 | 72.23 | 80.45 | 1.2 | | 10,396,645 | 665,385,305 |
| 26 Weeks | 84.35 | 70.08 | 76.72 | 6.2 | | 11,206,606 | 1,389,619,249 |
| 52 Weeks | 84.35 | 59.80 | 62.34 | 30.6 | | 10,172,457 | 2,543,114,353 |
| YTD | 84.35 | 72.05 | - | 7.7 | | 10,813,732 | 1,167,883,076 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 81.07 | 80.70 | 79.12 | 77.99 | 75.89 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -0.01 | 0.2 | 0.02 |
| Income | 0.07 | 0.7 | 0.12 |
| Dividend | 0.03 | 0.2 | 0.03 |
| Capital Spending | -0.01 | NA | -0.04 |
| R&D | 13.53 | NA | 4.06 |
| Normalized Inc. | -17.57 | NA | -3.61 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -9.0 | -9.0 | -1.6 |
| Earnings % | -8.5 | -8.5 | -1.5 |
| EPS % | -7.1 | -7.1 | -1.0 |
| EPS $ | -0.04 | -0.04 | -0.02 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 4.44 |
| Current Ratio | 1.2 |
| Quick Ratio (Acid Test) | 0.7 |
| Liquidity Ratio (Cash) | 0.76 |
| Receivables Turnover | 6.1 |
| Average Collection Period | 59 |
| Working Capital/Equity | 13.7 |
| Working Capital pS | 1.42 |
| Cash-Flow pS | 4.08 |
| Free Cash-Flow pS | 3.10 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.12 |
| Financial Leverage Ratio (Assets/Equity) | 0.9 |
| Debt Ratio | 30.4 |
| Total Debt/Equity (Gearing Ratio) | 0.94 |
| LT Debt/Equity | 0.74 |
| LT Debt/Capital Invested | 0.0 |
| LT Debt/Total Liabilities | 78.9 |
| Interest Cover | 12.3 |
| Interest/Capital Invested | 2.89 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 2.53 |
| Current P/E Ratio - LTM | 34.60 |
| Enterprise Value (EV)/EBITDA | 13.73 |
| Enterprise Value (EV)/Free Cash Flow | 28.22 |
| Dividend Yield | 2.5 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 7.59 |
| Price/Cash Flow Ratio | 19.4 |
| Price/Free Cash Flow Ratio - LTM | 25.8 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 23.7 |
| P/E Ratio (26 weeks ago) - LTM | 19.9 |
| P/E Ratio (52 weeks ago) - LTM | 17.3 |
| 5-Y High P/E Ratio | 26.5 |
| 5-Y Low P/E Ratio | 14.4 |
| 5-Y Average P/E Ratio | 36.5 |
| Current P/E Ratio as % of 5-Y Average P/E | 25 |
| P/E as % of Industry Group | 92.0 |
| P/E as % of Sector Segment | 132.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 22.0 |
| PER SHARE FIGURES |
| LT Debt pS | 7.35 |
| Current Liabilities pS | 8.24 |
| Tangible Book Value pS - LTM | -1.16 |
| Book Value pS - LTM | 10.70 |
| Capital Invested pS | 20.13 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 4.19 |
| Free Cash Flow pS - LTM | 3.15 |
| Earnings pS (EPS) | 2.34 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 19.64 |
| Free Cash Flow Margin 5YEAR AVG | 18.87 |
| Net Profit Margin | 0.2 |
| Net Profit Margin - 5YEAR AVRG. | 0.1 |
| Equity Productivity | 1.58 |
| Return on Equity (ROE) | 0.2 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.1 |
| Capital Invested Productivity | 0.82 |
| Return on Capital Invested (ROCI) | 0.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.1 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.1 |
| Gross Profit Margin | 68.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.6 |
| EBITDA Margin - LTM | 33.1 |
| EBIT Margin - LTM | 22.4 |
| Pre-Tax Profit Margin | 0.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.2 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 2.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 612,957 |
| Net Income per Employee | 90,145 |
| Average Collection Period | |
| Receivables Turnover | 6.1 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 2.6 |
| Inventory/Sales | 12.9 |
| Accounts Payble/Sales | 7.85 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 11.53 |
| Fixed Assets Turnover | 0.75 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 5.31 |
| Revenue per $ Plant | 3.18 |
| Revenue per $ Common Equity | 1.58 |
| Revenue per $ Capital Invested | 0.82 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 23.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 23.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 23.1 |
|
|  
| | |  |  | | |
